Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D

Open source

DOI: 10.1016/s1470-2045(15)00042-x
Published: 2015 Oct
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-15-00042-x,
  title = {Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.},
  author = {Hegewisch-Becker S and Graeven U and Lerchenmüller CA and Killing B and Depenbusch R and Steffens CC and Al-Batran SE and Lange T and Dietrich G and Stoehlmacher J and Tannapfel A and Reinacher-Schick A and Quidde J and Trarbach T and Hinke A and Schmoll HJ and Arnold D},
  year = {2015},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(15)00042-x},
  url = {https://doi.org/10.1016/s1470-2045(15)00042-x}
}

RIS

TY  - JOUR
TI  - Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
AU  - Hegewisch-Becker S
AU  - Graeven U
AU  - Lerchenmüller CA
AU  - Killing B
AU  - Depenbusch R
AU  - Steffens CC
AU  - Al-Batran SE
AU  - Lange T
AU  - Dietrich G
AU  - Stoehlmacher J
AU  - Tannapfel A
AU  - Reinacher-Schick A
AU  - Quidde J
AU  - Trarbach T
AU  - Hinke A
AU  - Schmoll HJ
AU  - Arnold D
PY  - 2015
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(15)00042-x
UR  - https://doi.org/10.1016/s1470-2045(15)00042-x
ER  -

APA

S, H., U, G., CA, L., B, K., R, D., CC, S., SE, A., T, L., G, D., J, S., A, T., A, R., J, Q., T, T., A, H., HJ, S., & D, A. (2015). Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(15)00042-x

Source records

pubmed · retrieved 2026-09-27T16:00:11.485Z
europe-pmc · retrieved 2026-09-27T16:00:11.492Z